Loading
A phase 2 trial of Oprelvekin in Leukaemia and Chronic myeloid leukaemia, run by M.D. Anderson Cancer Center, completed.
Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients is a phase 2 interventional study registered as NCT00493181 by M.D. Anderson Cancer Center, with 8 participants recorded, started 2005-10 and reaching its primary completion in 2011-01. Interventions recorded: Interleukin-11 (IL-11 or Neumega). Conditions recorded: Leukemia, Chronic Myelogenous Leukemia, Chronic Myeloid Leukemia.
Linked to the drug Oprelvekin because the registry names it among its interventions and Leukaemia and Chronic myeloid leukaemia among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
8 enrolled.
Figures from the ClinicalTrials.gov results section (first posted 2011-05-04), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Number of Participants With Complete Responseprimary | Interleukin-11 | 8 | 3 participants | - | - | link |
Shares Oprelvekin and the tag pipeline.
Shares Chronic myeloid leukaemia (CML) and the tag pipeline.
Shares Chronic myeloid leukaemia (CML), Leukaemia (all types) and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.
Shares Chronic myeloid leukaemia (CML) and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.